Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
March 07 2019 - 8:00AM
- Company to host conference call and webcast on
Tuesday, March 12 at 8:30 a.m. ET -
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
(“Corbus” or the “Company), a clinical stage drug development
company with the industry’s leading pipeline focused on treating
inflammatory and fibrotic diseases through the endocannabinoid
system pathways, today announced that the Company will host a
conference call and live audio webcast on Tuesday, March 12,
2019 at 8:30 a.m. ET to discuss operational and
financial results for the year ended December 31, 2018 as well
as provide a corporate update. The call will be led by Yuval
Cohen, Ph.D., Chief Executive Officer of Corbus. He will be joined
on the call by additional members of the Corbus management team.
Interested participants and investors may access the conference
call by dialing (877) 407-3978 (domestic) or (412) 902-0039
(international). The live webcast will be accessible on the Events
page of the Investors section of the Corbus website,
www.corbuspharma.com and will be archived for 90 days following the
event.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its pipeline of endocannabinoid
system-targeting synthetic drug candidates. The Company's lead
product candidate, lenabasum, is a novel, synthetic, oral,
selective cannabinoid receptor type 2 (CB2) agonist designed to
resolve chronic inflammation and fibrotic processes. Lenabasum is
currently being evaluated in systemic sclerosis, cystic fibrosis,
dermatomyositis, and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug
candidates from more than 600 novel compounds targeting the
endocannabinoid system. The pipeline includes CRB-4001, a 2nd
generation, peripherally-restricted, selective cannabinoid receptor
type 1 (CB1) inverse agonist designed to eliminate blood-brain
barrier penetration and subsequent brain CB1 receptor occupancy
that mediates the neuropsychiatric adverse events associated with
first-generation CB1 inverse agonists. Potential indications for
CRB-4001 include NASH, primary biliary cholangitis, idiopathic
pulmonary fibrosis, radiation-induced pulmonary fibrosis,
myocardial fibrosis after myocardial infarction and acute
interstitial nephritis, among others. Corbus plans to enter a Phase
1 study of CRB-4001 in 2019, intended to be followed by a National
Institutes of Health (NIH)-funded proof-of-concept Phase 2
study.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
Statements in this press release that are not
statements of historical fact are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, without limitation,
statements about Corbus’ expectations regarding the completion,
timing and size of its public offering and the anticipated use of
proceeds therefrom. Words such as “believe,” “anticipate,” “plan,”
“expect,” “intend,” “may,” “goal,” “potential” and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements necessarily contain these
identifying words. Among the factors that could cause actual
results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated
with market conditions as well as risks and uncertainties
associated with Corbus’ business and finances in general, including
the risks and uncertainties in the section captioned “Risk Factors”
in the prospectus supplement related to the public offering that
was filed with the SEC and the Company’s most recently filed Annual
Report on Form 10-K and subsequently filed Quarterly Reports on
Form 10-Q. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Corbus undertakes
no obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date of this press
release.
Corbus Investor Contacts:
Institutional Investor InquiriesTed Jenkins,
Senior Director, Investor Relations and CommunicationsCorbus
Pharmaceuticals, Inc.Phone: +1 (617) 415-7745Email:
ir@corbuspharma.com
All Other Investor InquiriesJenene ThomasJenene
Thomas Communications, LLCPhone: +1 (833) 475-8247Email:
crbp@jtcir.com
Media ContactCorbus Pharmaceuticals,
Inc.Lindsey SmithEmail: mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jul 2023 to Jul 2024